The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

Published

Journal Article

The purpose of this study was to analyze the impact of graft-versus-host disease (GVHD) on the relapse rate of different lymphoma subtypes after allogeneic hematopoietic cell transplantation (allo-HCT). Adult patients with a diagnosis of Hodgkin lymphoma, diffuse large B cell lymphoma, follicular lymphoma (FL), peripheral T cell lymphoma, or mantle cell lymphoma (MCL) undergoing HLA-identical sibling or unrelated donor hematopoietic cell transplantation between 1997 and 2009 were included. Two thousand six hundred eleven cases were included. A reduced-intensity conditioning (RIC) regimen was used in 62.8% of the transplantations. In a multivariate analysis of myeloablative cases (n = 970), neither acute (aGVHD) nor chronic GVHD (cGVHD) were significantly associated with a lower incidence of relapse/progression in any lymphoma subtype. In contrast, the analysis of RIC cases (n = 1641) showed that cGVHD was associated with a lower incidence of relapse/progression in FL (risk ratio [RR], .51; P = .049) and in MCL (RR, .41; P = .019). Patients with FL or MCL developing both aGVHD and cGVHD had the lowest risk of relapse (RR, .14; P = .007; and RR, .15; P = .0019, respectively). Of interest, the effect of GVHD on decreasing relapse was similar in patients with sensitive disease and chemoresistant disease. Unfortunately, both aGVHD and cGVHD had a deleterious effect on treatment-related mortality and overall survival (OS) in FL cases but did not affect treatment-related mortality, OS or PFS in MCL. This study reinforces the use of RIC allo-HCT as a platform for immunotherapy in FL and MCL patients.

Full Text

Duke Authors

Cited Authors

  • Urbano-Ispizua, A; Pavletic, SZ; Flowers, ME; Klein, JP; Zhang, M-J; Carreras, J; Montoto, S; Perales, M-A; Aljurf, MD; Akpek, G; Bredeson, CN; Costa, LJ; Dandoy, C; Freytes, CO; Fung, HC; Gale, RP; Gibson, J; Hamadani, M; Hayashi, RJ; Inamoto, Y; Inwards, DJ; Lazarus, HM; Maloney, DG; Martino, R; Munker, R; Nishihori, T; Olsson, RF; Rizzieri, DA; Reshef, R; Saad, A; Savani, BN; Schouten, HC; Smith, SM; Socié, G; Wirk, B; Yu, LC; Saber, W

Published Date

  • October 2015

Published In

Volume / Issue

  • 21 / 10

Start / End Page

  • 1746 - 1753

PubMed ID

  • 25981509

Pubmed Central ID

  • 25981509

Electronic International Standard Serial Number (EISSN)

  • 1523-6536

International Standard Serial Number (ISSN)

  • 1083-8791

Digital Object Identifier (DOI)

  • 10.1016/j.bbmt.2015.05.010

Language

  • eng